OncoCyte (OCX) Stock Price, News & Analysis

Company Overview

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Key Stats

• Today's Range: $2.71 to $3.21
• 50-Day Range: $2.60 to $3.44
• 52-Week Range: $2.56 to $3.50
• Volume: 100,514 shs
• Average Volume: 45,333 shs
• Market Capitalization: $90.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.75
• Consensus Rating: Buy

OCX Stock Analysis - Frequently Asked Questions

How were OncoCyte's earnings last quarter?

OncoCyte Corporation (NASDAQ:OCX) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The company had revenue of $2.14 million for the quarter, compared to analyst estimates of $0.13 million. OncoCyte had a negative net margin of 1,516.06% and a negative trailing twelve-month return on equity of 215.59%.
Read the conference call transcript.

When did OncoCyte's stock split?

OncoCyte's stock reverse split before market open on Tuesday, July 25th 2023.The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ford Motor (F).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OCX
• CIK: 1642380
• Web: oncocyte.com
• Phone: (949) 409-7600
• Fax: 510-521-3389
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OncoCyte: $6.75
• High Price Target: $8.00
• Low Price Target: $4.25
• Potential Upside/Downside: +112.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.66 million
• Net Margins: -1,516.06%
• Pretax Margin: -1,514.57%
• Return on Equity: -215.59%
• Return on Assets: -27.23%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 3.74
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: $3.84 million
• Price / Sales: 23.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.70) per share
• Price / Book: -4.54

Miscellaneous

• Outstanding Shares: 28,599,000
• Free Float: 28,013,000
• Market Cap: $90.80 million
• Optionable: No Data
• Beta: 0.97